HER2-targeted therapies in cancer: a systematic review

Biomarker Research

Table 1 Expression of HER2 in different cancers

HER2 Status Cancer Type	HER2 mutation			Amplification/Frequence(%)	Overexpression(%)	Reference
HER2 Status Cancer Type	Protein Change/Frequence(%)			Amplification/Frequence(%)	Overexpression(%)	Reference
Breast cancer	L755S	S310F	V777L	20	15-20	[5, 70,71,72]
Breast cancer	0.16-0.96	0.16-0.94	0.16-0.92	20	15-20	[5, 70,71,72]
Gastric cancer	S310F	S310Y	V842I	11–16	20	[73,74,75,76,77,78]
Gastric cancer	0.19-0.92	0.21-0.89	0.35-0.84	11–16	20	[73,74,75,76,77,78]
NSCLC	S310F	D277Y	G776delinsVC	2–3	2.5	[79, 80]
NSCLC	0.18-0.74	0.54-0.72	0.49-0.71	2–3	2.5	[79, 80]
Bladder cancer	R678Q	L313V	T733I	8.6	12.4-30	[74, 81, 82]
Bladder cancer	0.41-0.99	0.97	0.89-0.94	8.6	12.4-30	[74, 81, 82]
Biliary tract cancer	S310F	S310Y	D769Y	3–19	5-15	[18, 83,84,85,86,87,88]
Biliary tract cancer	0.27-0.96	0.24-0.94	0.23-0.83	3–19	5-15	[18, 83,84,85,86,87,88]
Colorectal cancer	S310F	M1014K	T862A	2-5.8	5	[89,90,91]
Colorectal cancer	0.24-0.89	0.77	0.73	2-5.8	5	[89,90,91]

ISSN: 2050-7771